Why Cingulate Inc.’s (CING) Stock Is Down 6.16%
As of Tuesday, November 03, Cingulate Inc.’s CING share price has dipped by 6.16%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Commentary & Analysis
Why Cingulate Inc.’s (CING) Stock Is Down 5.79%
As of Wednesday, October 28, Cingulate Inc.’s CING share price has dipped by 5.79%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Cingulate Inc.’s (CING) Stock Is Up 6.18%
As of Tuesday, October 27, Cingulate Inc.’s CING share price has surged by 6.18%, which has investors questioning if this is right time to sell.Michael Rose
Why Cingulate Inc.’s (CING) Stock Is Down 5.47%
As of Friday, October 16, Cingulate Inc.’s CING share price has dipped by 5.47%, which has investors questioning if this is right time to buy.Michael Rose
Why Cingulate Inc.’s (CING) Stock Is Down 5.03%
As of Wednesday, August 26, Cingulate Inc.’s CING share price has dipped by 5.03%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | CING | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $61.9 | $409.9 | 19% |
|
| Shares Out (Mil) | 13.2 | 44.5 | 24% |
|
| Institutional Ownership | 96.9% | 81.1% | 71% |
|
| Float (Mil) | 14.2 | 45.7 | 24% |
|
| Beta | -0.88 | 0.72 | 1% |
|
| Avg Daily Volume (000s) | 148 | 284 | 41% |
|
| Price Change (52-week) |
15.0% | 52.7% | 64% |
|
| Growth | CING | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 5.7% | na |
|
| Net Income (5yr) | (25.5%) | (2.0%) | 16% |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 4 | 4 | |
| Current EPS | ($0.447) | ($2.188) | ($0.880) | |
| Month Ago EPS | ($0.447) | ($2.188) | ($0.880) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.527) | ($2.300) | ($0.740) | |
| Year/Year Chg | 0.4% | (50.7%) | (77.0%) | |
| Financials | CING | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $326 | na |
|
| Net Income (TTM) (Mil) | ($29) | ($11) | 21% |
|
| EPS (TTM) | ($3.280) | ($0.600) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($21) | ($6) | 15% |
|
| Net Cash Flow (TTM) (Mil) | $20 | $2 | 62% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $6 | 17% |
|
| Enterprise Value (Q1) (Mil) | $53 | $466 | 17% |
|
| Valuation | CING | Industry Median |
Percentile (All Stocks) |
|
| P/B | 2.52 | 1.96 | 64% |
|
| P/E | na | 20.1 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | CING | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.7% | na |
|
| Net Margin | na | 3.4% | na |
|
| ROA | (123.8%) | (21.5%) | 4% |
|
| ROE | (198.7%) | (21.0%) | 4% |
|
| Liabilities to Assets | 29.0% | 31.8% | 20% |
|
| F-Score | 4 | 3 | 33% |
|
Cingulate Inc. did not pass any screens on 11/5/2026.
